Sinemet® Shortage Recommendations
July 23, 2019
Sinemet® (levodopa/carbidopa) is a medication commonly used in the treatment of Parkinson’s disease as well as other neurological disorders.
From 23 August 2018, there has been an international supply shortage of various formulations of Sinemet® including:
- Sinemet® 250/25 immediate release
- Sinemet ® 100/25 immediate release
- Sinemet® CR 200/50 controlled release
The shortage is expected to continue until 31 December 2019 and only emergency supplies for these products are available.
During this time, alternative products which are not on the Australian Register of Therapeutic Goods (ARTG), have been made available under Section 19A of the Therapeutics Goods Act. These include:
- Carbidopa and Levodopa tablets, USP 25mg/250mg
- Carbidopa and Levodopa Extended-release tablets 50mg/200mg
For more information regarding these products, contact Medsurge on 1300 788 261 or read the full statement regarding the shortage here.
Statement provided by the Australasian Neuroscience Nurses Association Movement Disorder Chapter and The Movement Disorder Society of Australia and New Zealand